Trials / Terminated
TerminatedNCT03251924
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate BMS-986226 administered alone or in combination with nivolumab or ipilimumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986226 | specified dose on specified days |
| BIOLOGICAL | Nivolumab | specified dose on specified days |
| BIOLOGICAL | Ipilimumab | specified dose on specified days |
| BIOLOGICAL | Tetanus Vaccine | specified dose on specified days |
Timeline
- Start date
- 2017-09-01
- Primary completion
- 2021-12-20
- Completion
- 2021-12-20
- First posted
- 2017-08-16
- Last updated
- 2023-02-28
- Results posted
- 2023-02-28
Locations
13 sites across 4 countries: United States, Canada, Spain, Switzerland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03251924. Inclusion in this directory is not an endorsement.